Tag: Alzheimer’s disease
Cognito announces OVERTURE II results indicating durable effects of Spectris treatment...
Cognito Therapeutics has announced treatment results from OVERTURE II—an open-label extension (OLE) study of Spectris, the company’s potential disease-modifying therapy for the treatment of...
Cognito presents MRI data showing efficacy of non-invasive gamma stimulation therapy...
Cognito Therapeutics has announced “robust, lobe-specific” changes in white matter volume and myelination in Alzheimer’s disease patients following six months of non-invasive gamma stimulation...
Cognito announces first patient enrolment in US pivotal study of novel...
Cognito Therapeutics has announced the first patient enrolment in its US pivotal study, HOPE, which is designed to demonstrate the safety and efficacy of...
Transcutaneous auricular VNS proves effective in patients with mild cognitive impairment
A double-blinded randomised controlled trial (RCT) has shown that transcutaneous auricular vagus nerve stimulation (taVNS) can improve cognitive performance in patients with mild cognitive...
Deep brain stimulation may fulfil “desperate need” for effective Alzheimer’s therapy
A team including researchers from the USA, Germany and Canada has found that stimulating a specific network in the brain of Alzheimer’s disease patients...
A new pathway for preventing dementia?
Craig Weinkauf (Tucson, USA) is leading a trial looking into a connection between Alzheimer's disease and carotid stenosis. "We want to try to quantify...
London clinic becomes first in UK to offer new drug-free Alzheimer’s...
The London Alzheimer’s Clinic on Harley Street (London, UK) has become the first clinic in the UK to offer transcranial pulse stimulation (TPS)—a “revolutionary”...
Sonocloud technology demonstrates safety and therapeutic potential in Alzheimer’s patients
Carthera has announced today the publication of results from an investigator-sponsored pilot clinical trial evaluating safety and efficacy using its Sonocloud technology in patients...
Intermittent theta-burst stimulation found to be effective and well-tolerated in Alzheimer’s...
The findings of a randomised controlled trial (RCT) have indicated that accelerated intermittent theta-burst stimulation (iTBS), administered to the left dorsolateral prefrontal cortex (DLPFC), is an...
White matter hyperintensities may hold key to identifying long-term harm in...
A new study has found that brain scans taken during the lifetimes of athletes in contact sports, compared to changes in their brains at...
Intranasal delivery of microrobots could trigger new possibilities in treating neurological...
A research team in South Korea has developed and successfully implanted a microrobot device into the brain tissue of mice through the intranasal pathway,...
Study indicates efficacy of hyperbaric oxygen therapy in reversing Alzheimer’s activators
A new study, published in the peer-reviewed medical journal Aging, marks the first time non-pharmaceutical clinical exploration has proved efficacious in reversing the main...
Revolution in neurotherapy? Spotlight on focused ultrasound at 2021 EAN congress
While focused ultrasound is by no means a brand-new innovation in the field of neurotherapy—having first been deployed in the 1950s, if not earlier,...
BioArctic receives European patent for antibodies targeting Alzheimer’s disease
BioArctic AB has announced that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for...
Physicians’ Education Resource releases agenda for the 1st Annual International Congress...
Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education (CME), announces the full agenda for the 1st Annual International Congress on...
Deep brain stimulation showing promise for patients with mild Alzheimer’s disease...
An age group analysis of data from the ADvance trial has shown that participants over the age of 65 continue to derive the most...
Fujifilm’s T-817MA Alzheimer’s drug fails to meet primary study endpoints
Fujifilm’s T-817MA drug has not met its primary study endpoints of cognition or global clinical function in its US Phase II clinical trial conducted...
Regional shortage of neurologists revealed across the USA
According to new data reported at the 2017 Alzheimer's Association International Conference (AAIC 2017, London, UK), multiple regions of the United States have been...
First Alzheimer’s trial with focused ultrasound begins
Researchers at Sunnybrook Health Sciences Centre in Toronto, Canada have begun the world’s first clinical trial evaluating the feasibility and safety of opening the...
Findings support role of vascular disease in development of Alzheimer’s disease
Among adults who entered a study more than 25 years ago, an increasing number of midlife vascular risk factors, such as obesity, high blood...
Hormone therapy may not protect against Alzheimer’s disease
The latest study on hormone therapy and Alzheimer’s disease shows no relationship between taking the drugs and developing the disease years later. Some previous...
First large, placebo-controlled double-blind stody of rTMS for Alzheimer’s receives funding
Funding for clinical trials of a new treatment for Alzheimer’s disease has been announced by the Weston Brain Institute, Toronto, Canada. Zahra Moussavi, Canada...
Neuronix submits neuroAD System for FDA clearance
Neuronix has announced positive results from its pivotal, double-blind placebo-controlled, multicentre clinical study, for the assessment of safety and efficacy of the neuroAD Therapy...
